Login to Your Account



Vivus Gains ED Approval; Obesity Still Center Stage

By Trista Morrison
Staff Writer

Monday, April 30, 2012

As expected, the FDA green-lighted Vivus Inc.'s erectile dysfunction drug Stendra (avanafil) on Friday, but analysts and investors remain focused on the looming July 17 PDUFA date for obesity drug Qnexa (phentermine/topiramate).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription